← Leaderboards
Anthony P Heaney
Cedars-Sinai Medical Center
$5,094,498
Attributed
$5,094,498
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $937K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,056,422 · 6
FDA$1,038,076 · 2
By mechanism
R01$4,144,010 · 4
R21$793,113 · 2
R03$154,167 · 1
M01$3,208 · 1
Top collaborators
No co-investigators on record.
Most similar at Cedars-Sinai Medical Center
Same institution · by research overlap
- Shlomo Melmed$23,916,451
- Odelia Cooper$1,272,521
- Ning-Ai Liu$776,250
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularGrowthMedicalPituitary NeoplasmsTumorIn VitroPituitary GlandNovel TherapeuticsExhibitsAffectHormone SecretionHigh Throughput ScreeningPrimary NeoplasmLibrariesDrug DiscoveryCellsMultidisciplinaryPharmaceutical PreparationsValidationImmune ResponseCell ModelIndividual PatientHigh-Throughput Drug ScreeningExtracellular Matrix
Grant awards (19)
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery$356,850
R01 · FY2025 · CA · contact PI
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease (IND 168501 - 07/31/2023)$424,824
R01 · FY2024 · FD · contact PI
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery$339,008
R01 · FY2024 · CA · contact PI
Development of a patient-derived tumoroid culture system to explore novel medical treatments for refractory prolactinomas$173,208
R21 · FY2024 · CA · contact PI
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery$349,713
R01 · FY2023 · CA · contact PI
Development of a patient-derived tumoroid culture system to explore novel medical treatments for refractory prolactinomas$218,790
R21 · FY2023 · CA · contact PI
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery$349,713
R01 · FY2022 · CA · contact PI
Identification of TR4 Modulators for Treatment of Cushing Disease.$401,115
R21 · FY2021 · CA · contact PI
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discovery$356,850
R01 · FY2021 · CA · contact PI
Refined Fructose Promotes Pancreatic Cancer Growth$255,440
R01 · FY2011 · CA · contact PI
Refined Fructose Promotes Pancreatic Cancer Growth$278,340
R01 · FY2010 · CA · contact PI
Refined Fructose Promotes Pancreatic Cancer Growth$278,340
R01 · FY2009 · CA · contact PI
Refined Fructose Promotes Pancreatic Cancer Growth$278,340
R01 · FY2008 · CA · contact PI
ROSIGLITAZONE TREATMENT IN PATIENTS WITH CUSHINGS DISEASEROSIGLITAZONE TREAT$3,208
M01 · FY2008 · RR · contact PI
ROSIALITAZONE: NOVEL THERAPY FOR PITUITARY TUMORS (PHAS*$286,462
R01 · FY2007 · FD · contact PI
Refined Fructose Promotes Pancreatic Cancer Growth$263,340
R01 · FY2007 · CA · contact PI
ROSIALITAZONE: NOVEL THERAPY FOR PITUITARY TUMORS (PHAS*$326,790
R01 · FY2006 · FD · contact PI
Chemoprevention of Pituitary Corticotroph Tumors$76,167
R03 · FY2006 · CA · contact PI
Chemoprevention of Pituitary Corticotroph Tumors$78,000
R03 · FY2005 · CA